Heat Biologics (HTBX) Enters Biomarker Discovery Collaboration with Adaptive Biotechnologies

October 11, 2016 7:33 AM EDT
Get Alerts HTBX Hot Sheet
Trade HTBX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Heat Biologics, Inc. (Nasdaq: HTBX) announced that they have advanced their biomarker discovery collaboration with Adaptive Biotechnologies. Adaptive will use its patented immune profiling assay, immunoSEQ™, to enable an in-depth characterization of the immune response to Heat’s ImPACT and ComPACT-based immunotherapies, including HS-410, Heat’s Phase 2 product candidate for non-muscle invasive bladder cancer. The immunoSEQ Assay, when used to evaluate the mechanism of action of the ImPACT platform, provides a significant biomarker identification opportunity to better select patients and accelerate future enrollment based on immune status.

“Previously reported data using Adaptive’s immunoSEQ Assay, demonstrated a trend between established anti-tumor immune responses and clinical outcomes with HS-410,” stated Taylor Schreiber, M.D., Ph.D., Heat’s Chief Scientific Officer. “The Adaptive Assay allows us to quantify the clonality of a T-cell response generated by our ImPACT platform. Future work should continue to be fruitful as we advance our understanding of the patients that benefit most from treatment.”



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News

Add Your Comment